Abstract
Low-dose acetylsalicylic acid (ASA) is recommended in patients with established cardiovascular disease. However, the role of ASA in those without cardiovascular disease (i.e., primary prevention) is less clear, which has led to discordance among Canadian guidelines. In 2018, 3 double-blind, randomized controlled trials were published that evaluated ASA 100 mg daily versus placebo in patients without established cardiovascular disease. In the ASPREE trial, ASA did not reduce the risk of all-cause death, dementia, or persistent physical disability in patients ≥70 years of age but increased the risk of major bleeding. In the ARRIVE trial, ASA failed to lower the risk of a composite of cardiovascular events but increased any gastrointestinal bleeding in patients at intermediate risk of cardiovascular disease. In the ASCEND trial, ASA significantly reduced the primary composite cardiovascular outcome in patients with diabetes for a number needed to treat of 91 over approximately 7.4 years. Yet major bleeding was increased with ASA for a number needed to harm of 112. Therefore, in most situations, ASA should not be recommended for primary cardiovascular prevention. However, there are additional indications for ASA beyond cardiovascul...Continue Reading
References
Jan 12, 2002·BMJ : British Medical Journal·UNKNOWN Antithrombotic Trialists' Collaboration
Jan 19, 2006·JAMA : the Journal of the American Medical Association·Jeffrey S BergerDavid L Brown
Jun 10, 2011·The Canadian Journal of Cardiology·Alan D BellUNKNOWN Canadian Cardiovascular Society
Nov 6, 2012·The New England Journal of Medicine·Timothy A BrightonUNKNOWN ASPIRE Investigators
Sep 10, 2014·Annals of Internal Medicine·Michael L LeFevre
Apr 22, 2015·American Journal of Preventive Medicine·Craig D WilliamsJessina C McGregor
Apr 12, 2016·Annals of Internal Medicine·Evelyn P WhitlockCorinne V Evans
Apr 12, 2016·Annals of Internal Medicine·Janelle M Guirguis-BlakeEvelyn P Whitlock
Apr 12, 2016·Annals of Internal Medicine·Kirsten Bibbins-Domingo, UNKNOWN U.S. Preventive Services Task Force
Apr 19, 2016·Diabetic Medicine : a Journal of the British Diabetic Association·S K KunutsorK Khunti
Sep 10, 2016·The Canadian Journal of Cardiology·Laurent MacleUNKNOWN CCS Atrial Fibrillation Guidelines Committee
Oct 30, 2016·The Canadian Journal of Cardiology·Todd J AndersonRichard Ward
Dec 20, 2016·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Feb 25, 2018·The Canadian Journal of Cardiology·Shamir R MehtaUNKNOWN members of the Secondary Panel
May 8, 2018·The Canadian Journal of Cardiology·Kara A NerenbergUNKNOWN Hypertension Canada
Aug 28, 2018·The New England Journal of Medicine·UNKNOWN ASCEND Study Collaborative GroupJane Armitage
Aug 31, 2018·Lancet·J Michael GazianoUNKNOWN ARRIVE Executive Committee
Oct 12, 2018·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Sheldon W TobePeter P Liu